Brain biomarkers · Alzheimer’s disease

Why p‑Tau matters.

Phosphorylated tau is helping medicine see Alzheimer’s biology earlier, more accurately and with a simple blood draw—but the result only becomes meaningful in the right clinical context.

Hanul Bhandari, MD · August 18, 2026 · 7-minute read

For generations, clinicians diagnosed Alzheimer’s disease largely by recognizing its clinical pattern and excluding other causes. Phosphorylated tau—especially p‑tau217—is changing that equation by offering a measurable window into the biology occurring inside the brain.

First: what is tau?

Tau is a normal protein found primarily inside neurons. One of its jobs is to help stabilize microtubules—the internal transport tracks that move nutrients and other essential material through a nerve cell.

“Phosphorylation” is a normal chemical process in which phosphate groups are added to a protein. The problem is not that tau is phosphorylated at all; it is that specific forms of tau become abnormally phosphorylated. The protein can detach from microtubules, change shape and ultimately collect into the neurofibrillary tangles associated with Alzheimer’s disease.

p‑Tau is not simply a marker of memory loss. It is a biomarker connected to a specific disease process.

Why are there different p‑Tau numbers?

The number identifies the amino-acid position at which tau is phosphorylated. The best-known blood biomarkers include p‑tau181, p‑tau217 and p‑tau231. They overlap, but they are not interchangeable.

Among currently studied blood markers, p‑tau217 has shown particularly strong performance for identifying Alzheimer’s-type amyloid pathology and separating Alzheimer’s disease from many non-Alzheimer causes of cognitive impairment. In a 2024 JAMA study of people with cognitive symptoms, percentage p‑tau217 alone achieved roughly 90% diagnostic accuracy in both primary- and secondary-care cohorts.³

A blood test crossed an important threshold

In May 2025, the FDA cleared the first blood test intended to aid in diagnosing Alzheimer’s disease: the Lumipulse G pTau217/β‑Amyloid 1‑42 Plasma Ratio. It is intended for adults age 55 and older who have signs or symptoms of cognitive decline and are being evaluated in a specialized care setting.¹

In the FDA-reviewed clinical study, 91.7% of people with positive results had amyloid plaques confirmed by amyloid PET or cerebrospinal-fluid testing. Among those with negative results, 97.3% had negative confirmatory testing. Fewer than 20% received an indeterminate result.¹

That is a meaningful advance. PET imaging is expensive and not universally accessible. A lumbar puncture is safe in experienced hands but remains invasive. A well-validated blood biomarker can make the diagnostic pathway faster and more scalable.

Why p‑Tau matters clinically

Greater diagnostic confidence. A p‑tau result can help determine whether Alzheimer’s pathology is likely to explain a patient’s cognitive syndrome.
Better triage. A clearly negative or positive result may reduce the number of people who need immediate PET or cerebrospinal-fluid confirmation, depending on the assay and clinical setting.
Earlier biological clarity. p‑Tau can become abnormal before dementia is advanced, creating an opportunity to identify disease during mild cognitive impairment or early dementia.
Treatment planning. Anti-amyloid therapies require evidence that Alzheimer’s amyloid pathology is present. Blood biomarkers may help determine who should proceed to confirmatory testing and a treatment-risk evaluation.
Research and monitoring. Plasma p‑tau217 tracks with Alzheimer’s pathology and cognitive decline over time, making it a promising outcome measure in trials—although routine treatment monitoring remains assay- and therapy-specific.⁵

What p‑Tau cannot tell us

A biomarker is not the whole patient. p‑Tau does not measure day-to-day function, establish the cause of every memory complaint or replace a neurological examination. It cannot, by itself, determine whether symptoms arise from Alzheimer’s disease, sleep apnea, medication effects, depression, vascular injury, seizures, vitamin deficiency—or a combination.

Important: The FDA-cleared p‑tau217/amyloid ratio is not intended as a stand-alone diagnosis or a general screening test for people without symptoms. False-positive, false-negative and indeterminate results occur, so the result must be interpreted with the clinical history and other data.¹

The 2025 Alzheimer’s Association clinical practice guideline therefore focuses on blood-based biomarkers in people with objective cognitive impairment who are being evaluated in specialty care. It uses performance-based standards and emphasizes that not every commercially available assay performs equally.²

The sleep–brain connection still matters

Biomarkers do not eliminate the need to look for modifiable contributors. Fragmented sleep, untreated obstructive sleep apnea, sedating or anticholinergic medications, metabolic disease and vascular risk can all affect cognition. Some may coexist with Alzheimer’s pathology and amplify its clinical expression.

That is why the best cognitive evaluation is integrated: characterize the cognitive syndrome, investigate potentially reversible contributors, assess sleep and neurological health, and use biomarkers when they answer a specific clinical question.

The bottom line

p‑Tau matters because it moves Alzheimer’s evaluation from inference toward biology. The most powerful question is not simply, “Is the number high?” It is: What does this result mean for this person, at this stage, with these symptoms and these other risks?

Used thoughtfully, p‑tau217 can shorten the path to clarity. Used without context, it can create confusion. The future of brain health belongs to precision—but precision still requires a physician to connect the dots.

References

This article is educational and does not provide a diagnosis or individualized medical advice. Biomarker selection and interpretation should be performed by a qualified clinician within a complete cognitive evaluation.